Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DFF003
MIFTS: 41

Diffuse Scleroderma

Categories: Immune diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Diffuse Scleroderma

About this section

MalaCards integrated aliases for Diffuse Scleroderma:

Name: Diffuse Scleroderma 12 15 73
Systemic Sclerosis, Diffuse 12
Diffuse Systemic Sclerosis 12
Systemic Scleroderma 73
Scleroderma, Diffuse 44

Classifications:

MalaCards categories:
Anatomical: Immune diseases Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1580
MeSH 44 D045743
NCIt 50 C116791
Sources

Summaries for Diffuse Scleroderma

About this section
MalaCards based summary : Diffuse Scleroderma, also known as systemic sclerosis, diffuse, is related to systemic scleroderma and scleroderma, familial progressive, and has symptoms including pruritus, exanthema and hidebound skin. An important gene associated with Diffuse Scleroderma is TOP1 (DNA Topoisomerase I), and among its related pathways/superpathways are NF-kappaB Signaling and Immune response IFN gamma signaling pathway. The drugs Bosentan and Ambrisentan have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and lung.

Sources

Related Diseases for Diffuse Scleroderma

About this section

Diseases related to Diffuse Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Related Disease Score Top Affiliating Genes
1 systemic scleroderma 32.9 TGFB1 TOP1 TRIM21
2 scleroderma, familial progressive 32.3 COL1A1 TOP1
3 limited scleroderma 29.4 MNDA PYHIN1 TOP1
4 collagen disease 29.4 COL1A1 TOP1 TRIM21
5 diffuse cutaneous systemic sclerosis 11.2
6 reynolds syndrome 11.1
7 phototoxic dermatitis 10.1 KNG1 TRIM21
8 lupus erythematosus 10.0
9 diffuse infiltrative lymphocytosis syndrome 10.0 TNFRSF10B TRIM21
10 crest syndrome 10.0
11 lung disease 10.0
12 hyperostosis 9.9 COL1A1 TGFB1
13 malignant essential hypertension 9.9 KNG1 TNFRSF25
14 ascending cholangitis 9.9 TGFB1 TNFRSF25
15 adie pupil 9.9 TNFRSF25 TRIM21
16 toxic diffuse goiter 9.9 TNFRSF10B TNFRSF25
17 heart block, congenital 9.9 TNFRSF25 TRIM21
18 systemic lupus erythematosus 9.9
19 skin disease 9.9
20 interstitial lung disease 9.9
21 subcorneal pustular dermatosis 9.9
22 punctate epithelial keratoconjunctivitis 9.8 TNFRSF25 TRIM21
23 chilblain lupus 1 9.8 TNFRSF25 TRIM21
24 autoimmune disease of musculoskeletal system 9.8 TNFRSF25 TOP1 TRIM21
25 breast cancer 9.7
26 ovarian cancer 9.7
27 pneumothorax, primary spontaneous 9.7
28 rheumatoid arthritis 9.7
29 aplastic anemia 9.7
30 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.7
31 polyarteritis nodosa, childhood-onset 9.7
32 pulmonary hypertension 9.7
33 arthritis 9.7
34 crohn's disease 9.7
35 dermatomyositis 9.7
36 thrombotic thrombocytopenic purpura 9.7
37 pneumothorax 9.7
38 purpura 9.7
39 kidney disease 9.7
40 bilateral breast cancer 9.7
41 polyarteritis nodosa 9.7
42 spondylocarpotarsal synostosis syndrome 9.7
43 autoimmune hepatitis 9.7
44 diabetes mellitus 9.7
45 hepatitis 9.7
46 steatorrhea 9.7
47 hepatitis a 9.7
48 gastric antral vascular ectasia 9.7
49 inner ear disease 9.7
50 mixed connective tissue disease 9.7

Graphical network of the top 20 diseases related to Diffuse Scleroderma:



Diseases related to Diffuse Scleroderma
Sources

Symptoms & Phenotypes for Diffuse Scleroderma

About this section

UMLS symptoms related to Diffuse Scleroderma:


pruritus, exanthema, hidebound skin
Sources

Drugs & Therapeutics for Diffuse Scleroderma

About this section

Drugs for Diffuse Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 323)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147536-97-8 104865
2
Ambrisentan Approved, Investigational Phase 4,Phase 2,Not Applicable 177036-94-1 6918493
3
Silver sulfadiazine Approved, Vet_approved Phase 4 22199-08-2 441244
4
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2 171596-29-5 110635
5
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
6
Metronidazole Approved Phase 4,Not Applicable 443-48-1 4173
7
Aspirin Approved, Vet_approved Phase 4,Not Applicable 50-78-2 2244
8
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 77-92-9 311
9 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Vaccines Phase 4,Not Applicable
11 Endothelin Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
14 Vasodilator Agents Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
15 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
18 Respiratory System Agents Phase 4,Phase 2,Phase 3
19 Platelet Aggregation Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
20 Autonomic Agents Phase 4,Phase 2,Phase 3,Early Phase 1
21 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Early Phase 1
22 Citrate Phase 4,Phase 3,Phase 2,Early Phase 1
23 Sildenafil Citrate Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 171599-83-0
24 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Acidophilus Phase 4,Phase 3
28 Bronchodilator Agents Phase 4
29 Fibrinolytic Agents Phase 4,Phase 2,Phase 3,Not Applicable
30 Phosphodiesterase 3 Inhibitors Phase 4
31 Anti-Asthmatic Agents Phase 4
32 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Antiparasitic Agents Phase 4,Not Applicable
36 Antiprotozoal Agents Phase 4,Not Applicable
37 Cyclooxygenase Inhibitors Phase 4,Not Applicable
38 Antipyretics Phase 4,Not Applicable
39 Omega 3 Fatty Acid Phase 4
40
Iloprost Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 78919-13-8 6443959
41
Acetylcysteine Approved, Investigational Phase 2, Phase 3,Phase 3 616-91-1 12035
42
Nitroglycerin Approved, Investigational Phase 3,Phase 2 55-63-0 4510
43
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
44
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Early Phase 1 83-43-2 6741
45
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Phase 3,Early Phase 1 302-25-0
46
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Early Phase 1 50-24-8 5755
47
rituximab Approved Phase 2, Phase 3,Phase 3,Not Applicable 174722-31-7 10201696
48
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Phase 3,Early Phase 1 2921-57-5
49
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
50
Methocarbamol Approved, Vet_approved Phase 3,Phase 2 532-03-6 4107

Interventional clinical trials:

(show top 50) (show all 404)
# Name Status NCT ID Phase Drugs
1 Influenza Vaccination in Patients With Scleroderma Unknown status NCT01002508 Phase 4
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis Completed NCT02480335 Phase 4 bosentan
4 Bosentan in Systemic Sclerosis Completed NCT01395732 Phase 4 Bosentan
5 Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan Completed NCT01051960 Phase 4 Ambrisentan
6 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis Completed NCT01042158 Phase 4 tadalafil and ambrisentan upfront combination therapy
7 Pulmonary Artery Remodelling With Bosentan Completed NCT00595049 Phase 4 bosentan
8 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
9 Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases Recruiting NCT03388255 Phase 4 Polydeoxyribonucleotides
10 To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis Recruiting NCT03053739 Phase 4 Sildenafil 20mg and Bosentan 62.5mg;Sildenafil 20mg and Placebo
11 Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis Recruiting NCT03692299 Phase 4 Saccharomyces Boulardii Oral Tablet;Metronidazole
12 Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients Enrolling by invitation NCT03558854 Phase 4 Acetylsalicylic acid;Placebo oral capsule
13 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
14 Comparison of Esophageal and Anorectal Manometry Catheters Terminated NCT00204763 Phase 4
15 Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis Withdrawn NCT01497743 Phase 4 Lactobacillus
16 Intraoperative ICG for Systemic Sclerosis Withdrawn NCT03155464 Phase 4 Indocyanine Green
17 Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis Unknown status NCT02302352 Phase 3
18 High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis Unknown status NCT00428883 Phase 2, Phase 3 N-acetylcysteine (NAC)
19 Serial Night Time Position Splint on Systemic Sclerosis Unknown status NCT01586663 Phase 3 Drug treatment
20 Platelet Gel in Systemic Sclerosis Unknown status NCT00463125 Phase 2, Phase 3 Platelet Gel
21 A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3 Nitroglycerin;Topical AmphiMatrix
22 Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms Unknown status NCT00934427 Phase 3 0.9% nitroglycerin in TAM cream;vehicle cream
23 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
24 Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma Completed NCT00704665 Phase 3 Relaxin;Relaxin
25 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
26 Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients Completed NCT01474109 Phase 3 macitentan 3mg;macitentan 10mg;placebo
27 Rituximab in Systemic Sclerosis Completed NCT01748084 Phase 2, Phase 3 Rituximab;Placebo (NaCl)
28 Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis Completed NCT00348296 Phase 3 High-dose intravenous immunoglobulin (Venoglobulin-IH)
29 Effectiveness and Safety of Lidocaine for Scleroderma Completed NCT00740285 Phase 2, Phase 3 Lidocaine 2% without vessel constrictor
30 Gastroesophageal Reflux Treatment in Scleroderma Completed NCT01878526 Phase 3 Alginic acid;placebo (for domperidone);Domperidone;placebo (of alginic acid)
31 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
32 Scleroderma: Cyclophosphamide or Transplantation (SCOT) Completed NCT00114530 Phase 2, Phase 3 cyclophosphamide
33 A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis Completed NCT02597933 Phase 3 Nintedanib;Placebo
34 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
35 Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma Completed NCT00077584 Phase 3 Bosentan 62.5 mg;Bosentan 125 mg;Placebo
36 Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension Completed NCT00984932 Phase 3 Rosuvastatin
37 Scleroderma Lung Disease Completed NCT00004563 Phase 3 Cyclophosphamide;Placebo
38 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
39 Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease Completed NCT02896205 Phase 3 Mycophenolate mofetil;Placebo
40 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3 Tadalafil;Placebo
41 A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
42 A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis Completed NCT01532869 Phase 3 Placebo;tocilizumab [RoActemra/Actemra];tocilizumab [RoActemra/Actemra]
43 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT00626665 Phase 3 Tadalafil
44 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT00004786 Phase 3 iloprost
45 Open-label Study With Bosentan in Interstitial Lung Disease Completed NCT00319033 Phase 2, Phase 3 bosentan
46 Bosentan in Digital Ulcers Completed NCT00319696 Phase 3 Bosentan 62.5 mg;Bosentan 125 mg
47 Imiquimod in Children With Plaque Morphea Completed NCT00147771 Phase 3 Imiquimod 5% cream
48 A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Completed NCT00498615 Phase 3 Fasudil
49 Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00266669 Phase 3 Topical organogel with nitroglycerin
50 Lab Study of MQX-503 in Treatment of Raynaud's Completed NCT00253331 Phase 2, Phase 3 topical organogel with nitroglycerin

Search NIH Clinical Center for Diffuse Scleroderma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: scleroderma, diffuse

Sources

Genetic Tests for Diffuse Scleroderma

About this section
Sources

Anatomical Context for Diffuse Scleroderma

About this section

MalaCards organs/tissues related to Diffuse Scleroderma:

41
Skin, Bone, Lung, Heart, Kidney, Breast, Bone Marrow
Sources

Publications for Diffuse Scleroderma

About this section

Articles related to Diffuse Scleroderma:

(show top 50) (show all 83)
# Title Authors Year
1
Subcorneal Pustular Dermatosis: A Case Report of a Patient with Diffuse Scleroderma. ( 29930923 )
2018
2
Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. ( 30053212 )
2018
3
Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease. ( 28337853 )
2017
4
Predicting improvement in diffuse scleroderma: lessons learnt. ( 27221693 )
2016
5
Splenic Pseudoaneursym as the Cause of Recurrent Gastrointestinal Bleeding in a Woman With Diffuse Scleroderma. ( 26157926 )
2015
6
Subcutaneous calcifications in a patient with diffuse scleroderma. ( 23910621 )
2013
7
Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. ( 20058013 )
2012
8
Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. ( 20679474 )
2011
9
Reversible posterior leukoencephalopathy in diffuse scleroderma. ( 20576217 )
2010
10
A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. ( 19812599 )
2010
11
Squamous cell carcinomas in 2 patients with diffuse scleroderma treated with mycophenolate mofetil. ( 19208586 )
2009
12
Subcorneal pustular dermatosis in a patient with rheumatoid arthritis and diffuse scleroderma. ( 19379649 )
2009
13
Autologous stem cell transplantation in diffuse scleroderma: impact on hand structure and function. ( 18336540 )
2008
14
Current approaches to the management of early active diffuse scleroderma skin disease. ( 18329538 )
2008
15
High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. ( 17381465 )
2007
16
A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. ( 15769789 )
2005
17
Kidney disease other than renal crisis in patients with diffuse scleroderma. ( 15801020 )
2005
18
The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. ( 14679295 )
2004
19
Bilateral breast cancer associated with diffuse scleroderma. ( 14659331 )
2003
20
Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. ( 12605319 )
2003
21
Methotrexate for the treatment of early diffuse scleroderma: comment on the article by Pope et al. ( 11920427 )
2002
22
Unusual overlap of systemic lupus erythematosus and diffuse scleroderma. ( 11247318 )
2001
23
Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. ( 11157146 )
2001
24
Pseudohypertension in a patient with diffuse scleroderma. ( 11273902 )
2001
25
A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. ( 11407694 )
2001
26
Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. ( 10943881 )
2000
27
Severe organ involvement in systemic sclerosis with diffuse scleroderma. ( 11083266 )
2000
28
Minocycline in early diffuse scleroderma. ( 9848358 )
1998
29
Prevalence of pulmonary hypertension in limited and diffuse scleroderma. ( 8989070 )
1996
30
Thrombotic thrombocytopenic purpura in a patient with diffuse scleroderma. ( 9251403 )
1996
31
Seizures in a patient with diffuse scleroderma. ( 7494776 )
1995
32
Interstitial Lung Disease Developing during Treatment with Cyclosporine in a patient with Diffuse Scleroderma, Aplastic Anemia and Crohn's Disease: Implications for Pathogenesis and Treatment. ( 19077999 )
1995
33
Genetic and immunological differences between Japanese patients with diffuse scleroderma and limited scleroderma. ( 8151564 )
1994
34
Autonomic dysfunction in diffuse scleroderma vs CREST: an assessment by computerized heart rate variability. ( 7837149 )
1994
35
A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma. ( 2003858 )
1991
36
Ketotifen-induced remission in progressive early diffuse scleroderma: evidence for the role of mast cells in disease pathogenesis. ( 2393046 )
1990
37
Clinical association of autoantibodies to fibrillarin with diffuse scleroderma and disseminated telangiectasia. ( 2254467 )
1990
38
Progressive systemic sclerosis (diffuse scleroderma) and radiotherapy. ( 2242481 )
1990
39
Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. ( 2787182 )
1989
40
Mast cell numbers in diffuse scleroderma. ( 3813593 )
1987
41
Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma. ( 3490227 )
1986
42
Scl-86, a marker antigen for diffuse scleroderma. ( 3980727 )
1985
43
Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. ( 6690931 )
1984
44
Myocardial function and perfusion in the CREST syndrome variant of progressive systemic sclerosis. Exercise radionuclide evaluation and comparison with diffuse scleroderma. ( 6475990 )
1984
45
Landmark article May 23, 1942: Diffuse collagen disease. Acute disseminated lupus erythematosus and diffuse scleroderma. By Paul Klemperer, Abou D. Pollack and George Baehr. ( 6366270 )
1984
46
Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. ( 6628005 )
1983
47
Acute diffuse scleroderma. ( 6165202 )
1981
48
Reversible acute renal faiure in diffuse scleroderma. ( 7408249 )
1980
49
Progressive systemic sclerosis (diffuse scleroderma). A follow-up report of treatment with potaba. ( 4576830 )
1973
50
Esophageal reconstruction for stenosis due to diffuse scleroderma. Utilizing blunt dissection of esophagus. ( 4783042 )
1973
Sources

Variations for Diffuse Scleroderma

About this section
Sources

Expression for Diffuse Scleroderma

About this section
Search GEO for disease gene expression data for Diffuse Scleroderma.
Sources

Pathways for Diffuse Scleroderma

About this section

Pathways related to Diffuse Scleroderma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
NF-kappaB Signaling 4
11.85 MNDA TNFRSF10B TNFRSF25
2
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.45 TGFB1 TNFRSF10B TNFRSF25
3
Apoptosis and Autophagy 4
11.07 MNDA TNFRSF10B TNFRSF25
4
Syndecan-2-mediated signaling events 1
10.47 KNG1 TGFB1
Sources

GO Terms for Diffuse Scleroderma

About this section

Cellular components related to Diffuse Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.96 KNG1 TGFB1
2 collagen-containing extracellular matrix GO:0062023 8.8 COL1A1 KNG1 TGFB1

Biological processes related to Diffuse Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.63 COL1A1 TGFB1 TOP1
2 regulation of apoptotic process GO:0042981 9.54 TGFB1 TNFRSF10B TNFRSF25
3 cellular response to transforming growth factor beta stimulus GO:0071560 9.48 COL1A1 TGFB1
4 positive regulation of epithelial to mesenchymal transition GO:0010718 9.43 COL1A1 TGFB1
5 leukocyte migration GO:0050900 9.43 COL1A1 TGFB1 TNFRSF10B
6 protein destabilization GO:0031648 9.4 PYHIN1 TRIM21
7 face morphogenesis GO:0060325 9.32 COL1A1 TGFB1
8 positive regulation of apoptotic process GO:0043065 9.26 KNG1 MNDA TGFB1 TNFRSF10B
9 positive regulation of protein localization to nucleus GO:1900182 9.16 PYHIN1 TGFB1
10 cellular response to mechanical stimulus GO:0071260 8.8 COL1A1 TGFB1 TNFRSF10B
Sources

Sources for Diffuse Scleroderma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....